Cushing Syndrome

Cushing syndrome (CS) is a clinical state resulting from chronic, inappropriate exposure to excessive levels of glucocorticoids, most commonly cortisol. This perturbation of the hypothalamic-pituitary-adrenal (HPA) axis is categorized by the source of the hormone excess and the degree of dependence on adrenocorticotropic hormone (ACTH).

Synonyms and Abbreviations

• CS: Cushing syndrome (general term for hypercortisolism)
• CD: Cushing disease (specifically pituitary ACTH-secreting adenoma)
• EAS: Ectopic ACTH syndrome
• MACS: Mild autonomous cortisol secretion (formerly "subclinical Cushing syndrome")
• PBMAH: Primary bilateral macronodular adrenal hyperplasia

Classification and Nomenclature

CS is fundamentally divided into ACTH-dependent and ACTH-independent forms. ACTH-dependent CS (approximately 80% of cases) involves hypersecretion of ACTH, which drives bilateral adrenal cortisol production. ACTH-independent CS (approximately 20%) arises from autonomous adrenal cortisol production, which suppresses endogenous ACTH via negative feedback ^[1]D5[9]B3b.

Clinical Variants and Severity

Hypercortisolism exists on a continuum of severity and temporal patterns. Overt Cushing syndrome presents with classic catabolic features, whereas mild autonomous cortisol secretion (MACS) is defined by a post- dexamethasone suppression test cortisol level >1.8 μg/dL in the absence of overt clinical signs ^[9]B3b.

Cyclical Cushing syndrome is a distinct subentity characterized by repeated episodes of cortisol excess (peaks) followed by periods of normal or low secretion (troughs) ^[1]D5. Its prevalence is estimated between 14% and 18% of CS cases ^[1]D5. Clinicians must distinguish between true cyclicity and the more common phenomenon of marked cortisol variability, as both can lead to paradoxical biochemical results ^[1]D5. In the ectopic subtype, a distinction is often made between "aggressive" EAS (often small cell lung carcinoma with abrupt onset <3-6 months) and "indolent" EAS (often carcinoid tumors with progressive onset >6 months) ^[7]D5.

Establishing these definitions is critical for navigating the subsequent biochemical signature and axis physiology.

Pearl: Cushing syndrome is a biochemical continuum; MACS is defined by a post-dexamethasone cortisol >1.8 μg/dL even without overt physical signs, while cyclical CS may present with paradoxical eucortisolism during troughs ^[1]D5[9]B3b.

The hypothalamic-pituitary-adrenal (HPA) axis maintains homeostasis through a tightly regulated feedback loop that, when disrupted, results in the chronic glucocorticoid excess defining this syndrome ^[27]D5. Under physiological conditions, hypothalamic corticotropin-releasing hormone (CRH) stimulates the anterior pituitary to secrete adrenocorticotropic hormone (ACTH), which then induces the adrenal cortex to produce cortisol ^[19]D5. Cortisol exerts negative feedback at both the hypothalamic and pituitary levels to suppress further secretion; however, in pathological states, this loop is either bypassed by autonomous production or subverted by aberrant signaling pathways ^[21]D5[27]D5.

Mechanisms of HPA Axis Disruption

Pathogenesis is broadly categorized by the source of the hormonal driver and the status of the feedback mechanism. In ACTH-dependent forms, the primary defect is the autonomous secretion of ACTH, which drives bilateral adrenal hyperplasia and continuous cortisol production ^[16]C4. In ACTH-independent forms, the adrenal glands themselves become the source of autonomous cortisol, leading to the suppression of endogenous ACTH ^[15]C4[17]D5.

1. Pituitary Autonomy ( Cushing Disease ): Neoplastic corticotroph cells in the pituitary secrete ACTH despite high circulating cortisol. While these cells often retain partial sensitivity to high-dose glucocorticoids, the normal set point for feedback is lost ^{[11]A1a[22]D5}.
2. Ectopic ACTH Secretion (EAS): Non-pituitary tumors, such as thymic neuroendocrine tumors or gastrointestinal malignancies, produce ACTH or CRH ^[26]C4[30]D5. These tumors typically lack glucocorticoid receptors or possess molecular alterations, such as POMC promoter hypomethylation, that allow for a paradoxical positive-feedback loop where glucocorticoids further stimulate ACTH production ^[13]C4[14]C4.
3. Adrenal Autonomy: Somatic mutations, such as those in the PRKACA gene (p.Leu206Arg or p.Ser213Arg), interfere with the regulatory and catalytic subunits of protein kinase A, leading to constitutive cortisol production regardless of ACTH levels ^[16]C4.
4. Aberrant Receptor Expression: In conditions like pregnancy or primary bilateral macronodular adrenal hyperplasia (PBMAH), adrenal cells may aberrantly express receptors for luteinizing hormone (LH), human chorionic gonadotropin (hCG), or gastric inhibitory polypeptide, causing cortisol surges in response to non-ACTH physiological stimuli ^[17]D5[31]D5.

Biochemical Signatures and Diagnostic Patterns

The biochemical fingerprint of the syndrome is defined by the relationship between ACTH and cortisol, as well as the response to dynamic stimulation or suppression ^[11]A1a.

Molecular and Genetic Susceptibility

Genetic variants significantly influence the clinical phenotype and the severity of the biochemical signature. Loss-of-function mutations in the NR3C1 gene (encoding the glucocorticoid receptor) can cause generalized glucocorticoid resistance, characterized by high ACTH and cortisol levels without the clinical features of Cushing syndrome, as the peripheral tissues are insensitive to the hormone ^[12]C4[21]D5. Conversely, variations in the SERPINA6 gene, which encodes corticosteroid-binding globulin (CBG), alter the buffering and delivery of cortisol to tissues, potentially predisposing individuals to metabolic or neuropsychiatric complications even at lower total cortisol concentrations ^[19]D5.

Systemic Pathophysiological Consequences

Chronic hypercortisolism drives multi-organ dysfunction through direct genomic effects and crosstalk with other endocrine systems ^[20]D5.

• Adipose-Adrenal Crosstalk: Excess cortisol promotes visceral adiposity and insulin resistance while altering adipokine secretion, which may further modulate adrenal tumor biology through paracrine signaling ^[20]D5.
• Skeletal Degradation: Glucocorticoids directly inhibit osteoblast function and increase osteoclast activity, leading to rapid bone loss even in mild autonomous cortisol secretion (MACS) ^[25]D5.
• Androgen Excess: In ACTH-dependent forms, the stimulation of the adrenal zona reticularis leads to increased adrenal androgens, manifesting as hirsutism (mFG score > 4-6) ^[18]D5.

Pearl: The biochemical hallmark of ectopic ACTH is the loss of negative feedback; a paradoxical rise in ACTH following dexamethasone administration suggests a positive-feedback loop often driven by POMC promoter hypomethylation ^[13]C4[14]C4.

Endogenous hypercortisolism arises from a spectrum of neoplastic and genetic drivers that disrupt the hypothalamic-pituitary-adrenal axis, shifting the homeostatic state toward allostasis ^[19]D5. The incidence of endogenous Cushing syndrome (CS) is estimated at 4.84 to 3.77 per million person-years, with a strong female predominance of 80.0% and a mean age at diagnosis of 45.3 years ^[33]B2b.

Etiological Distribution

Etiology is broadly categorized by ACTH dependence, which dictates the localization strategy. In nationwide cohort data, adrenal-source CS (ACTH-independent) accounts for 64.6% of cases, while Cushing disease (pituitary ACTH-dependent) represents 35.4% ^[33]B2b.

• Adrenal Adenomas and Hyperplasia: Functioning adrenal incidentalomas (AI) have an overall prevalence of 27.5% ^[32]A1a. Autonomous cortisol secretion (ACS) is the most frequent hormonal alteration in AI, occurring in 11.7% of patients ^[32]A1a.
• Ectopic ACTH Secretion (EAS): Often associated with lung carcinoids, which are classified by the WHO based on molecular markers and mitotic activity ^[5]D5.
• Genetic Drivers: Somatic mutations are identified in 71.8% of cortisol-producing adenomas ^[36]C4.
• PRKACA mutations are most frequent in overt CS (43.8%) ^[36]C4.
• CTNNB1 mutations occur in 56.5% of mild autonomous cortisol secretion (MACS) cases ^[36]C4.
• ARMC5 pathogenic variants are present in 22.9% of patients with bilateral macronodular adrenocortical disease (BMAD) and correlate with larger tumor diameter and higher cortisol levels ^[42]C4.
• McCune-Albright Syndrome (MAS): CS occurs in 7.1% of MAS patients, typically presenting at a median age of 3 months ^[38]C4.

Risk Factors and Comorbidities

Hypercortisolism is frequently under-recognized in high-risk metabolic populations. In patients with diabetes, the prevalence of confirmed CS is 2.1%, while 14.3% exhibit an abnormal dexamethasone suppression test (DST) ^[44]A1a.

Cardiovascular and Neoplastic Risk

CS confers a significant burden of systemic sequelae that may persist after biochemical cure. Patients have a higher risk of all-cause cancer (SIR 2.08), particularly liver (27.7%), kidney (16.7%), and lung (13.0%) malignancies ^[33]B2b. Cardiovascular complications are prominent; pre-existing atrial fibrillation/flutter is more common in CS than controls (3.6% vs 2.1%, OR 1.70) ^[35]B2b. Furthermore, patients with adrenal adenomas demonstrate a higher proportion of visceral fat (OR 2.2 for CS) and lower skeletal muscle area (OR 0.01 for CS) compared to referent subjects ^[39]B3b.

Pearl: Screening for CS should be prioritized in patients with difficult-to-control diabetes or hypertension, as 2.1% of diabetics may harbor undiagnosed hypercortisolism ^[44]A1a.

The transition from biochemical hypercortisolism to clinical phenotype is driven by chronic glucocorticoid excess, which disrupts the bidirectional crosstalk between the adrenal glands and adipose tissue ^[20]D5. This disruption leads to a characteristic shift in energy homeostasis, manifesting as visceral adiposity and insulin resistance ^[20]D5. While many features overlap with common metabolic conditions, the presence of multiple progressive signs, particularly proximal muscle weakness and wide purple striae, increases the clinical probability of endogenous hypercortisolism ^[53]D5.

Presenting Symptoms

Patients typically present with a constellation of metabolic and physical changes that progress over months to years. In cases of ectopic ACTH secretion, such as those arising from pheochromocytoma or thymic neuroendocrine tumors, the onset may be more rapid and accompanied by severe refractory hypertension and hypokalemia ^{[50]A1a[56]C4[57]C4}.

• Metabolic and Weight Changes: Rapid weight gain with central distribution, development of type 2 diabetes mellitus (reported in 54% of ectopic cases ^[50]A1a), and progressive fatigue ^[52]C4.
• Dermatologic Findings: Easy skin bruising, wide (>1 cm) purple striae, and facial plethora ^[51]C4[52]C4.
• Musculoskeletal Complaints: Proximal muscle weakness (difficulty climbing stairs or rising from a chair), bone fractures, and growth retardation in pediatric patients ^[51]C4[56]C4.
• Neuropsychiatric Symptoms: Irritability, cognitive or developmental disorders (observed in 44.4% of McCune-Albright cases ^[38]C4), and sleep disturbances ^[38]C4[51]C4.

Neurological and Physical Examination

A structured examination should focus on the distribution of adipose tissue and the integrity of the musculoskeletal and vascular systems.

• Adipose Distribution: Centripetal obesity with a "buffalo hump" (dorsocervical fat pad), increased supraclavicular fat, and "Cushingoid facies" (moon face) ^[38]C4[51]C4.
• Motor System: Symmetrical proximal muscle wasting and weakness, particularly in the pelvic girdle.
• Vascular/Autonomic: Hypertension is nearly universal in severe forms, occurring in 93% of ACTH-secreting pheochromocytomas ^[50]A1a.
• Cranial Nerves: In rare cases of pituitary blastoma , patients may present with ophthalmoplegia due to local tumor destruction ^[54]C4.

Phenotypic Variants

Red Flags and Atypical Presentations

Clinicians must maintain a high index of suspicion for underlying malignancies or acute complications when specific "red flags" appear. In pediatric populations, the combination of growth deceleration and weight gain is a hallmark of iatrogenic or endogenous excess ^[51]C4.

• Refractory Hypertension and Hypokalemia: Strongly suggests an ectopic ACTH source, such as a pheochromocytoma ^{[50]A1a[57]C4}.
• Acute Stroke or Hypertensive Crisis: Reported in pediatric adrenocortical tumors ^[55]C4.
• Comorbid Heart/Liver Disease: In McCune-Albright syndrome, these are poor prognostic markers (Heart disease OR 13.3 for mortality) ^[38]C4.
• Atypical Pediatric Presentation: May present as premature pubarche, virilization, or incidental findings after trauma ^[55]C4.

Pearl: The combination of growth arrest and weight gain in a child is pathognomonic for glucocorticoid excess until proven otherwise ^[51]C4.

Establishing the diagnosis of endogenous hypercortisolism requires a rigorous, two-stage biochemical engine: first, the confirmation of hypercortisolemia, and second, the localization of its source through paired hormone analysis and dynamic suppression or stimulation testing ^[63]D5. Because clinical features often overlap with common metabolic conditions, biochemical screening is only indicated in patients with a high pre-test probability or those with unusual features for their age, such as osteoporosis or hypertension ^[63]D5.

History and Physical

• Clinical Signs: Elicit specific findings including proximal muscle weakness, wide (>1 cm) purple striae, facial plethora, and supraclavicular fat pads ^[63]D5.
• Comorbidities: Screen for new-onset or refractory hypertension (93%), diabetes (54%), and cardiovascular complications ^[50]A1a.
• Red Flags: Rapid onset of symptoms, severe hypokalemia, and refractory hypertension often suggest an ectopic ACTH source ^[57]C4.
• Exogenous Review: Systematically exclude all forms of glucocorticoid use, including herbal remedies or supplements which may be adulterated with undeclared steroids ^[28]D5.

First-Line Screening Tests

Confirmation of endogenous hypercortisolism requires at least two positive results from the following first-line tests ^[63]D5:

Step-by-Step Diagnostic Algorithm

1. Exclude Exogenous Use: Confirm no recent oral, inhaled, topical, or injected glucocorticoid exposure ^[63]D5[28]D5.
2. Biochemical Screening: Perform at least two first-line tests (ODST, UFC, or LNSC). If results are discordant or mildly elevated, repeat testing or use a different first-line modality ^[63]D5.
3. Plasma ACTH Measurement: Once hypercortisolism is confirmed, measure morning plasma ACTH to differentiate the source ^[63]D5.

• ACTH <5 pg/mL: ACTH-independent (adrenal source). Proceed to adrenal CT ^[63]D5.
• ACTH >20 pg/mL: ACTH-dependent (pituitary or ectopic source). Proceed to dynamic testing and pituitary MRI ^[63]D5.
• ACTH 5-20 pg/mL: Indeterminate; requires a CRH stimulation test to clarify the axis ^[63]D5.

4. Localization: Use dynamic biochemical tests (CRH, desmopressin, or high-dose dexamethasone) and imaging to distinguish Cushing disease (CD) from ectopic ACTH syndrome (EAS) ^[11]A1a.

Dynamic and Localization Testing

In ACTH-dependent cases, the Corticotropin-Releasing Hormone (CRH) test is the most accurate dynamic study, demonstrating a sensitivity of 86.9% for CD and a specificity of 93.9% for EAS ^[11]A1a. A positive ACTH response after CRH administration (typically a >20% increase) highly suggests a pituitary source ^[11]A1a.

Inferior Petrosal Sinus Sampling (IPSS)

IPSS remains the gold-standard diagnostic test for differentiating CD from EAS when non-invasive testing is inconclusive ^[67]D5. It involves catheterization of the petrosal sinuses with concurrent peripheral ACTH measurement, often enhanced by desmopressin or CRH stimulation ^[70]B2b.

• Traditional Cutoffs: An IPS-to-peripheral (IPS:P) ACTH ratio >2.0 (basal) or >3.0 (stimulated) confirms CD ^[70]B2b.
• Optimized Cutoffs: Recent data suggest lower cutoffs (basal >1.49 or stimulated >2.26) improve sensitivity to 97.4% while maintaining 100% specificity ^[70]B2b.
• Adjuncts: Prolactin measurement during IPSS is used to confirm adequate venous efflux from the pituitary ^[67]D5.

Imaging Modalities

• Pituitary MRI: The first-line imaging for ACTH-dependent CS; however, up to 40% of corticotroph adenomas are not visible on standard MRI ^[63]D5.
• Adrenal CT: Indicated for ACTH-independent CS. Features such as contralateral adrenal thinning (limb width correlation with post-ODST cortisol r = -0.583) help distinguish autonomous secretion from non-functioning masses ^[69]B3b.
• Functional Imaging: 68Ga-DOTATATE PET/CT or 68Ga-pentixafor PET/CT may be utilized to localize occult ectopic sources or differentiate primary aldosteronism with coexisting subclinical CS ^[71]B3b.

Controversies and Guideline Disagreement

Pearl: Never perform localization imaging or IPSS until hypercortisolism is biochemically proven; incidentalomas are common and can lead to the surgical resection of non-secreting lesions ^[63]D5[67]D5.

Risk stratification in endogenous hypercortisolism relies on a composite of biochemical intensity, clinical symptom burden, and the underlying etiology. While benign adrenal Cushing syndrome (CS) carries a standardized mortality ratio (SMR) of 3.0 (95% CI, 2.4-3.7), malignant adrenal CS ( adrenocortical carcinoma ) exhibits an SMR of 13.1 (95% CI, 7.6-18.6), necessitating immediate surgical prioritization ^[34]B2b.

Biochemical and Clinical Severity Scoring

Biochemical severity is quantified by the degree of cortisol excess, often using 24-hour urinary free cortisol (UFC) or serum cortisol levels. Higher baseline biochemical severity scores are independent predictors of the magnitude of metabolic improvement following surgical remission ^[73]B2b.

• Hypertension Improvement: Associated with higher biochemical scores (OR 1.3, 95% CI 1.1-1.5) ^[73]B2b.

Clinical severity scores, which aggregate features like myopathy, skin thinning, and neuropsychiatric symptoms, correlate with postoperative recovery trajectories. Moderate to severe clinical severity scores are associated with a longer duration of postoperative adrenal insufficiency (β=8.7) and a higher burden of glucocorticoid withdrawal syndrome (GWS) ^{[74]B2b[80]B2b}.

Risk Stratification by Etiology and Comorbidity

The risk of long-term sequelae varies significantly between overt CS and mild autonomous cortisol secretion (MACS). Although MACS is often considered "subclinical," these patients exhibit sleep impairment and muscle strength deficits (mean sit-to-stand Z-score -0.47) comparable to overt CS (Z-score -0.54) ^{[68]B2b[76]B3b}.

Prognostic Factors in Ectopic and Rare Syndromes

In patients with ectopic CS secondary to thymic neuroendocrine tumors (Thy-NETs), female gender and the presence of bone metastases are associated with a worse prognosis, whereas co-occurrence with Multiple Endocrine Neoplasia Type 1 (MEN1) may suggest a better prognosis (5-year overall survival 85%) ^[26]C4. In McCune-Albright syndrome (MAS), CS typically presents in the neonatal period; severe multisystem involvement, including polyostotic fibrous dysplasia, serves as a marker for increased mortality risk ^[83]B3b.

Postoperative Recovery Stratification

Stratifying patients by their risk of GWS and prolonged adrenal insufficiency (AI) guides the choice of replacement therapy. Prednisone may be superior to hydrocortisone for improving mental health-related quality of life (SF-36 mental component estimate 0.33, 95% CI 0.04-0.63) during the first 12 weeks postsurgery ^[75]B2b. The median time to recovery of the HPA axis is significantly shorter in MACS (3.9 months) compared to overt CS (13.5 months) ^[74]B2b.

Pearl: Baseline biochemical severity is a "double-edged sword": higher scores predict a greater likelihood of reversing diabetes and hypertension but also a significantly higher risk of severe glucocorticoid withdrawal syndrome and prolonged adrenal insufficiency ^{[73]B2b[74]B2b[80]B2b}.

Acute complications in active disease necessitate hospitalization in up to 62% of patients with pituitary sources and 100% of those with ectopic ACTH secretion ^[84]B3b. These emergencies often manifest before a formal diagnosis is established, with 23% of patients requiring hospitalization for acute complications prior to the suspicion of hypercortisolism ^[84]B3b. Management focuses on the rapid stabilization of metabolic, cardiovascular, and infectious crises while simultaneously initiating biochemical control of cortisol excess.

Step-by-Step Emergency Protocol

1. Identify and Stabilize Life-Threatening Complications Screen for and treat the most prevalent acute events: infections (25%), thromboembolic events (17%), hypokalemia (13%), and hypertensive crises (9%) ^[84]B3b. In pediatric populations, be vigilant for acute stroke due to hypertensive crisis or acute kidney injury (AKI) secondary to urolithiasis ^[55]C4[89]C4.

2. Initiate Rapid Cortisol Suppression In critically ill patients or those with severe hypercortisolism, etomidate is the only available intravenous option for rapid cortisol reduction ^[86]C4. It is primarily used in intensive care unit (ICU) settings (84.3% of cases) and has a survival rate to definitive treatment of 80.9% ^[86]C4. Faster cortisol reduction is associated with higher baseline cortisol levels, the use of a prior bolus dose, and higher initial infusion rates ^[86]C4.

3. Manage Co-Secretory States and Feedback Loops In cases of ectopic ACTH-secreting pheochromocytoma , initiate alpha-blockade with phentolamine or doxazosin before addressing hypercortisolism to prevent a steroid-induced catecholamine crisis ^[88]C4[91]D5. Be aware that metyrapone may paradoxically decrease both ACTH and catecholamine levels in these patients by interrupting a glucocorticoid-driven positive-feedback loop ^[13]C4[88]C4.

4. Address Metabolic and Mechanical Sequelae Manage diabetic ketoacidosis (DKA) and refractory hypokalemia aggressively ^[13]C4[90]C4. For patients with AKI due to bilateral ureteral stones, continuous renal replacement therapy and ureteral stenting may be required alongside cortisol suppression ^[89]C4.

5. Transition to Definitive Therapy Once biochemical and physiological stability is achieved, proceed to definitive surgical resection of the primary lesion (e.g., adrenalectomy or pituitary surgery) ^[13]C4[89]C4.

Controversies and Guideline Disagreement

What NOT to Do

• Do NOT perform a biopsy on suspected pediatric adrenocortical tumors; it increases the risk of tumor rupture, metastasis, and death ^[55]C4.
• Do NOT administer dexamethasone if an ACTH-secreting pheochromocytoma is suspected, as it may paradoxically increase ACTH and catecholamine secretion ^[13]C4.
• Do NOT overlook supplement history; abrupt cessation of products like Artri Ajo King can precipitate secondary adrenal insufficiency ^[87]C4.

Pearl: Etomidate is the first-line intravenous agent for severe Cushing syndrome in the ICU, facilitating rapid cortisol reduction and allowing 80.9% of patients to survive until definitive surgical intervention ^[86]C4.

Following the stabilization of acute metabolic crises, long-term management focuses on the definitive resolution of hypercortisolism while mitigating the persistent morbidity associated with chronic glucocorticoid exposure. Even after achieving biochemical remission, patients often face increased mortality and a high burden of cardiovascular, metabolic, and musculoskeletal comorbidities ^[93]B2a (2a). Management strategies are categorized into definitive surgical cure, medical suppression of steroidogenesis, and the management of postoperative adrenal insufficiency (AI).

Step 1: Definitive Surgical Intervention

Surgical resection remains the first-line curative approach for most etiologies. For pituitary sources, transsphenoidal surgery is standard, while adrenal causes typically require adrenalectomy .

• Laparoscopic Adrenalectomy: Preferred for masses <6 cm without high suspicion of malignancy ^[46]B3b (3b). In patients with obesity (BMI ≥30 kg/m²), there is a trend toward higher postoperative complications (15.0% vs 4.3%, p=0.07), though operative time and hospital stay remain comparable to non-obese patients ^[46]B3b.
• Unilateral Adrenalectomy in PBMAH: Effective for primary bilateral macronodular adrenal hyperplasia (PBMAH) with overt features, achieving remission in small cohorts (median follow-up 14 months) ^[9]B3b (3b).
• Ectopic Sources: Surgical resection of the primary tumor (e.g., lung carcinoids or pheochromocytoma) leads to rapid normalization of ACTH and cortisol ^[5]D5[57]C4 (5, 4).

Step 2: Medical Suppression and Chronotherapy

Medical therapy is indicated for patients who are not surgical candidates, those with persistent disease postoperatively, or as a bridge to radiation effects ^{[24]D5[100]D5} (5).

• Steroidogenesis Inhibitors: Agents such as metyrapone , ketoconazole , and osilodrostat block specific enzymatic steps. Osilodrostat has demonstrated efficacy across various etiologies, including adrenal CS (response rate 87.5% after 12 weeks) and paraneoplastic syndrome, where it can normalize urinary free cortisol (UFC) within a median of 2 weeks ^{[98]B3b[99]B3b} (3b).
• Mild Hypercortisolism (mH): Low-dose evening metyrapone (250-500 mg/day) can improve blood pressure control, with 40% of patients achieving a ≥5 mmHg reduction in mean 24-hour systolic BP ^[101]B2b (2b).

Step 3: Postoperative Replacement and Withdrawal Management

Successful surgery often results in transient or permanent AI, requiring glucocorticoid replacement and management of glucocorticoid withdrawal syndrome (GWS).

• Replacement Selection: Prednisone may be superior to hydrocortisone for mental health-related quality of life (QoL) at 12 weeks postsurgery (SF-36 mental component estimate 0.33, 95% CI 0.04-0.63) ^[75]B2b (2b).
• Duration of AI: The median time to recovery is significantly shorter in mild autonomous cortisol secretion (MACS) compared to overt CS (3.9 months vs 13.5 months, p < 0.001) ^[74]B2b (2b). Preoperative 1-mg dexamethasone suppression test (DST) levels >5 μg/dL in MACS patients increase the risk of requiring replacement beyond 1 year by 4-fold ^[106]B2b (2b).
• GWS Symptoms: Common during the first 12 weeks post-remission, including myalgias/arthralgias (50%), fatigue (45%), and mood changes (19%) ^[80]B2b (2b).

Step 4: Monitoring and Treat-to-Target Goals

Biochemical control is the primary target, but normalization of the circadian rhythm is increasingly recognized as a secondary goal for psychological well-being.

• Late-Night Salivary Cortisol (LNSC): Normalization of LNSC in biochemically controlled patients correlates with better anxiety and depression scores compared to those with abnormal LNSC ^[105]B3b (3b).
• Residual Risk: Inflammatory biomarkers often remain elevated even 24 months after biochemical cure, suggesting persistent cardiovascular risk ^[102]B3b (3b).

Controversies and Guideline Disagreement

Dosing Table

What NOT to Do

• Do NOT perform a biopsy on suspected pediatric adrenocortical tumors; it increases the risk of tumor rupture and metastasis ^[55]C4 (4).
• Do NOT assume biochemical remission equals comorbidity normalization; active surveillance for cardiovascular and bone health must continue indefinitely ^{[93]B2a[102]B3b} (2a, 3b).
• Do NOT overlook the risk of relapsing autoimmune conditions (e.g., immune thrombocytopenia) when rapidly correcting hypercortisolism ^[104]C4 (4).

Pearl: Postoperative recovery is a dual process of hypercortisolism resolution and glucocorticoid withdrawal; using prednisone may improve mental health QoL during the first 12 weeks of this transition ^{[75]B2b[80]B2b}.

Surgical remission of hypercortisolism remains the definitive therapeutic goal, as it significantly reverses the metabolic and cardiovascular burden associated with the disease ^[73]B2b. Over the last century, the understanding of pathologic cortisol secretion has evolved from Harvey Cushing's initial descriptions to the recognition of subtle, subclinical presentations that previously escaped diagnosis ^[118]D5. The therapeutic timeline has shifted from aggressive, often morbid interventions toward targeted surgical and medical strategies designed to mitigate the long-term sequelae of glucocorticoid excess.

Evolution of Surgical Outcomes

Modern surgical management focuses on achieving biochemical remission to reverse systemic comorbidities. In a prospective cohort study (2019-2025), surgical remission led to significant improvements in hypertension , diabetes mellitus (DM), and obesity at 12 months post-surgery ^[73]B2b. The degree of improvement is often proportional to the baseline biochemical severity of the disease ^[73]B2b.

• Hypertension: Improvement occurred in 70% of patients with Cushing syndrome (CS) and 51% of those with mild autonomous cortisol secretion (MACS) ^[73]B2b.
• Diabetes Mellitus: Remission or improvement was noted in 90% of CS patients compared to 37% of MACS patients ^[73]B2b.
• Obesity: Weight reduction was achieved in 79% of CS patients and 20% of MACS patients ^[73]B2b.
• MACS Management: A randomized trial of 132 patients demonstrated that adrenalectomy significantly improved weight, glucose, and blood pressure control compared to conservative management ^[114]A1b. Adrenalectomy was independently associated with improved weight control (OR 10.38) and glucose control (OR 5.30) ^[114]A1b.

Abandoned and Refined Approaches

Historical reliance on bilateral adrenalectomy for pituitary-derived disease has largely been superseded by transsphenoidal surgery, though adrenalectomy remains a critical salvage therapy or primary treatment for specific genetic syndromes. In McCune-Albright syndrome (MAS), where CS often presents in infancy (median age 3 months), the high mortality rate (20%) associated with comorbid heart disease often necessitates prompt bilateral adrenalectomy ^[38]C4. Conversely, spontaneous resolution occurs in some MAS cases, though these patients require long-term monitoring for late-onset adrenal insufficiency ^[38]C4.

Medical Management and Emerging Challenges

Medical therapy, such as metyrapone , is increasingly used as a bridge to surgery or in cases where surgery is contraindicated. In pediatric patients with Carney complex and primary pigmented nodular adrenocortical disease (PPNAD), long-term metyrapone has been shown to normalize cortisoluria over a 2-year period, potentially delaying the need for bilateral adrenalectomy ^[119]C4. However, rapid correction of hypercortisolism can trigger complications, such as the relapse of immune thrombocytopenia (ITP), due to the loss of endogenous glucocorticoid-mediated immunosuppression ^[104]C4.

Controversies and Guideline Disagreement

Pearl: Surgical remission reverses diabetes in up to 90% of patients with overt Cushing syndrome, but clinicians must monitor for glucocorticoid withdrawal syndrome and the unmasking of underlying autoimmune conditions during the recovery phase ^{[73]B2b[104]C4}.

Inherited tumor syndromes and somatic genetic aberrations frequently drive the pathogenesis of Cushing syndrome (CS), necessitating a multidisciplinary approach to cross-axis surveillance. While most cases are sporadic, the clustering of adrenocortical tumors with other endocrine neoplasms often signals an underlying germline predisposition, such as Multiple Endocrine Neoplasia Type 1 (MEN1), Li-Fraumeni syndrome, or Beckwith-Wiedemann syndrome ^[5]D5[55]C4.

Genetic Drivers and Somatic Mutations

Somatic mutations are identified in approximately 71.8% of cortisol-producing adenomas (CPAs) ^[36]C4. The genetic profile differs significantly between overt Cushing syndrome (OCS) and mild autonomous cortisol excess (MACE). In OCS, the cyclic adenosine monophosphate-dependent protein kinase A (PKA) pathway is frequently activated via PRKACA mutations (43.8%), whereas CTNNB1 mutations (Wnt/β-catenin pathway) predominate in MACE (56.5%) ^{[36]C4[121]D5}. GNAS mutations, which also stimulate steroidogenesis, are more common in MACE (71.4% of all GNAS mutations) but have been reported in rare cases of oncocytic adrenocortical carcinoma ^{[36]C4[103]C4}.

Co-Axis Suppression and Hormonal Crosstalk

Chronic hypercortisolism exerts a severity-dependent suppression on the hypothalamic-pituitary-gonadal (HPG) and thyroid axes ^[82]B3b. The gonadal axis appears more susceptible to glucocorticoid excess than the thyroid axis ^[82]B3b.

• HPG Axis: Ectopic ACTH syndrome (EAS) causes the most profound suppression, characterized by markedly reduced luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels ^[82]B3b. Conversely, EAS is associated with markedly elevated testosterone, which may aid in discriminating it from other subtypes ^[82]B3b.
• Hirsutism: Excess androgens contribute to hirsutism in approximately 10% of women globally, though CS remains a rare cause compared to polycystic ovary syndrome (80-90%) ^[18]D5.
• Pregnancy: ACTH-independent CS during pregnancy is often driven by adrenal adenomas aberrantly expressing LH receptors, which are activated by rising human chorionic gonadotropin (hCG) levels ^[17]D5.

Multiglandular and Syndromic Presentations

Ectopic ACTH or CRH production can arise from catecholamine-secreting pheochromocytoma , a rare but critical diagnostic consideration in patients with ACTH-dependent CS and an adrenal mass ^[50]A1a. In these cases, 93% of patients present with hypertension and 54% with diabetes ^[50]A1a. Furthermore, subclinical CS frequently coexists with primary aldosteronism (PA-SCS). These patients typically have larger adrenal lesions (2.24 cm vs 1.10 cm in isolated PA) and higher lesion-to-contralateral ratios on 68Ga-pentixafor PET/CT ^[71]B3b.

Systemic Metabolic and Tissue Effects

Glucocorticoid excess disrupts the bidirectional crosstalk between the adrenal cortex and adipose tissue, leading to visceral adiposity and insulin resistance ^[20]D5. In patients with obesity, the prevalence of an abnormal dexamethasone suppression test (DST) is 4.6%, with confirmed CS in 0.8% ^[44]A1a. Among patients with diabetes, the prevalence of an abnormal DST rises to 14.3%, with confirmed CS in 2.1% ^[44]A1a. Beyond metabolic dysfunction, even subtle endogenous excess is detrimental to bone health, increasing the risk of osteoporosis ^[25]D5. Cardiovascular surveillance is essential, as CS is associated with an increased risk of new-onset atrial fibrillation or flutter (HR 1.55, 95%), a risk that persists despite biochemical remission ^[35]B2b.

Pearl: Systematically screen for co-secretion and genetic syndromes in young patients or those with bilateral adrenal disease, as somatic CTNNB1 mutations or germline predispositions significantly alter the long-term surveillance strategy ^[36]C4[55]C4.

Hypercortisolism induces multisystemic damage through direct glucocorticoid receptor signaling and indirect metabolic disruption, often persisting despite biochemical remission. The transition from active disease to recovery is frequently complicated by glucocorticoid withdrawal syndrome (GWS), a complex state where persisting central and peripheral adaptations to high cortisol meet relative deficiency during tapering ^[23]D5. This syndrome manifests across musculoskeletal, gastrointestinal , and neuropsychiatric domains, mimicking adrenal insufficiency even when circulating levels are technically within the reference range ^[23]D5.

Cardiometabolic and Vascular Complications

Chronic cortisol excess drives a distinct phenotype of visceral adiposity and skeletal muscle wasting. Patients with Cushing syndrome (CS) and mild autonomous cortisol secretion (MACS) exhibit significantly higher visceral fat (CS OR 2.2; MACS OR 2.0) and lower skeletal muscle area compared to matched controls ^[39]B3b. For every 1 µg/dL increase in cortisol after dexamethasone suppression, the visceral fat to muscle area ratio increases by 2.3 ^[39]B3b.

• Dyslipidemia and Hypertension : Hypercortisolism disrupts adipose tissue crosstalk, leading to insulin resistance and hypertension ^[20]D5. Surgical remission improves hypertension in 70% of CS patients and 51% of MACS patients at 12 months ^[73]B2b.
• Arrhythmias: CS is associated with a significantly higher risk of new-onset atrial fibrillation or flutter (HR 1.55), a risk that persists despite remission and is primarily driven by coexisting cardiovascular comorbidities ^[35]B2b.
• Liver Disease: Liver steatosis prevalence ranges from 20% to 66% in CS ^[48]D5. While some evidence suggests cortisol may have anti-inflammatory effects in the liver, metabolic dysfunction-associated steatotic liver disease is common, particularly in pediatric patients with obesity ^[41]C4[48]D5.

Musculoskeletal and Reproductive Sequelae

Glucocorticoid excess impairs bone health through direct effects on osteoblasts and indirect suppression of the hypothalamic-pituitary-gonadal (HPG) axis ^{[25]D5[82]B3b}.

• Bone Health: Patients with CS are more likely to have osteoporosis than those with nonfunctioning tumors, and overt CS carries a significantly higher risk of fragility fractures ^[69]B3b. Even subtle endogenous excess is detrimental to bone mineral density ^[25]D5.
• Reproductive Dysfunction: CS causes severity-dependent suppression of the HPG axis ^[82]B3b. In women, this manifests as reduced LH and FSH levels and elevated testosterone, with the most pronounced suppression observed in ectopic ACTH syndrome ^[82]B3b.

Mortality and Long-term Surveillance

Endogenous CS is associated with increased all-cause mortality, which may not fully normalize following treatment ^{[93]B2a[120]A1a}. In benign adrenal CS, the standardized mortality ratio (SMR) is 3.0, rising to 13.1 in malignant cases ^[34]B2b. Residual risks for coronary artery disease, stroke, and depression remain high postoperatively, necessitating lifelong surveillance ^{[34]B2b[93]B2a}.

Pearl: Remission of hypercortisolism does not equate to a return to baseline health; systemic inflammatory biomarkers and cardiovascular risks often persist for years, requiring active management of comorbidities beyond cortisol normalization ^{[93]B2a[102]B3b}.

Remission of hypercortisolism significantly improves clinical outcomes, yet patients often face a protracted recovery characterized by residual metabolic and psychological morbidity. The natural history of untreated Cushing syndrome is marked by progressive cardiovascular decay, while treated patients enter a phase of systemic transition where the resolution of hypercortisolemia competes with the morbidity of glucocorticoid withdrawal ^{[80]B2b[93]B2a}.

Long-term Mortality and Comorbidities

Even after achieving biochemical remission, patients with endogenous Cushing syndrome (CS) exhibit a persistent increase in mortality and morbidity compared to the general population ^[93]B2a. The standardized mortality ratio (SMR) is particularly elevated in adrenal CS, reaching 3.0 for benign cases and 13.1 for malignant adrenocortical carcinoma ^[34]B2b.

• Metabolic and Bone Health: Diabetes mellitus improves in 90% of CS patients post-remission, with higher baseline biochemical severity predicting greater improvement (OR 2.5) ^[73]B2b. While active CS induces significant bone marrow fat (BMF) accumulation in the femur (82.5% vs 70.8% in controls), BMF levels typically normalize after an average remission time of 43 months ^[123]B3b.
• Neuropsychiatric Outcomes: Quality of life and cognitive functioning improve post-treatment but frequently fail to reach the levels of healthy control populations ^[95]A1a.

Glucocorticoid Withdrawal Syndrome (GWS)

Surgical remission triggers a clinical state of withdrawal that can complicate the early postoperative period (first 12 weeks). Baseline clinical severity is the primary predictor of GWS burden ^[80]B2b.

• Prevalent Symptoms: Myalgias and arthralgias (50%), fatigue (45%), and weakness (34%) ^[80]B2b.
• Trajectory: While CushingQoL scores may improve by 12 weeks, physical component scores often worsen as myalgias and weakness peak between weeks 5 and 12 ^[80]B2b.

Prevention and Screening

Prevention focuses on early detection in high-risk populations and cascade screening for genetic variants.

• Targeted Screening: In patients with obesity, the prevalence of confirmed CS is 0.8%, rising to 2.1% in those with diabetes ^[44]A1a. Screening is particularly warranted in patients with recent weight gain or poorly controlled type 2 diabetes ^[44]A1a.
• Genetic Cascade Screening: Identification of germline mutations, such as ARMC5 in primary bilateral macronodular adrenal hyperplasia (PBMAH), allows for the identification of asymptomatic carriers and early intervention in family members ^[9]B3b.
• Pediatric Vigilance: In children, nonclassical presentations like acute stroke or premature pubarche require immediate endocrine evaluation to prevent diagnostic delays that lead to tumor rupture or metastasis ^[55]C4.

Prognostic Variants

Pearl: Remission is not a restoration of the pre-morbid state; clinicians must maintain lifelong surveillance for cardiovascular events and persistent cognitive impairment even after cortisol normalization ^{[93]B2a[95]A1a}.

Prognostic outcomes and management strategies in hypercortisolism are heavily influenced by the patient's physiologic state, with pregnancy and pediatric development requiring specific diagnostic and therapeutic adjustments. The transition from long-term management to specialized care involves addressing unique biochemical signatures and altered risk profiles in these cohorts.

Pregnancy and Fertility

Hypercortisolism during pregnancy is rare and frequently misdiagnosed due to overlapping features with normal gestation, such as weight gain, fatigue, and striae ^[17]D5. The etiology is most commonly an adrenal adenoma, followed by pituitary-dependent disease ^[17]D5. In some cases, ACTH-independent disease is driven by the aberrant expression of luteinizing hormone (LH) receptors in the adrenal cortex, where pregnancy-associated rises in human chorionic gonadotropin (hCG) activate cortisol production ^[17]D5.

• Diagnosis: Assessment is complicated by the natural rise in maternal hormones and binding proteins. Diagnosis relies on the loss of plasma cortisol diurnal rhythm and elevated ACTH or cortisol levels ^[131]C4.
• Management: Laparoscopic adrenalectomy is a primary intervention for adrenal sources ^[17]D5. Medical management is reserved for cases where surgery is not feasible or must be delayed. Ketoconazole and metyrapone are used, though their use requires careful titration to avoid maternal-fetal complications ^[24]D5.
• Nelson Syndrome: Women with Nelson syndrome (ACTH-secreting pituitary tumor following bilateral adrenalectomy) require multidisciplinary care. Management includes visual field checks and parenteral hydrocortisone during delivery to manage stress-dose requirements ^[130]A1a.

Pediatrics

Pediatric presentation is distinct, often characterized by growth failure and delayed bone age rather than the rapid weight gain seen in adults ^[107]D5. Adrenocortical tumors (ACT) in children are frequently functional and show age-dependent and sex-dependent phenotypes ^[127]B3b.

• Clinical Presentation: In prepubertal girls, common signs include pubarche (68.3%) and clitoral hypertrophy (49.2%); in prepubertal boys, pubarche (55.9%) and penile growth (47.1%) predominate ^[127]B3b. Pubertal patients more frequently present with hypertension and cushingoid appearance ^[127]B3b.
• Rare Etiologies: Pituitary blastoma is a rare infancy-onset tumor (median age 11 months) often associated with DICER1 syndrome ^[54]C4. McCune-Albright syndrome may cause hypercortisolism, typically in the neonatal period or early infancy ^[83]B3b.
• Complications: Hypertension is prevalent, affecting 44% to 74% of pediatric patients depending on the subtype ^[128]B3b. While surgery often improves blood pressure, 16% to 21% of patients may have residual systolic hypertension one year postoperatively ^[128]B3b.

Surgical and Perioperative Considerations

Perioperative risk is heightened by the immunosuppressive effects of hypercortisolism. Inflammatory biomarkers, specifically the neutrophil-to-lymphocyte ratio (NLR), are significantly higher in pediatric patients with active disease compared to controls ^[129]B3b.

• Infection Risk: Independent risk factors for perioperative infection include a 1-mg dexamethasone suppression test (DST) result ≥ 17.2 µg/dL, a prognostic nutritional index (PNI) ≤ 51.4, and the presence of diabetes mellitus ^[132]B3b.
• Thromboprophylaxis: ACTH-dependent disease carries a high risk of venous thromboembolism (VTE). Routine prophylaxis with rivaroxaban 10 mg once daily has been shown to be safe and effective, with no major bleeding complications reported in clinical cohorts ^[66]B2b.

Pearl: In pediatric patients, the absence of obesity does not rule out the diagnosis; weight gain mediates some but not all cortisol-associated complications, and growth velocity impairment remains a more sensitive marker ^{[41]C4[107]D5}.